FDA Misgivings About Reprints Would Not Make Them "False" - WLF Lawyer
This article was originally published in The Gray Sheet
Executive Summary
FDA would not be permitted to object to off-label reprints as "false and misleading" because the agency has technical problems with an article under the recent Washington Legal Foundation v. Henney ruling on off-label dissemination, Daniel Troy of the Washington D.C. law firm of Wiley, Rein & Fielding, asserted.
You may also be interested in...
WLF Decision Opens Door To Off-Label Promotion With Journal Reprints
Manufacturers can promote products for off-label uses with studies sponsored by competitors, according to the July 28 federal court decision against the FDA Modernization Act in Washington Legal Foundation v. Henney.
Vanda Comes Up Empty Handed As US Supreme Court Denies Hetlioz Appeal
Vanda looks likely to have to face up to unimpeded US generic competition to its core Hetlioz brand, after a further denial in its litigation against ANDA sponsors Teva and Apotex.
EU: Good News For IVDs And For Future Transparency Of Medtech Compliance
The IVD industry has long been awaiting a further extension of the deadlines for compliance with the IVD Regulation and for the launch date of the Eudamed database to be brought forward.